Novartis (NVS) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Novartis (NVS) quarterly earnings & revenue
Novartis (NVS) reported revenue of $13.52B for Q1 2026, down 0.7% year-over-year, with net income of $3.16B and diluted EPS of $1.65.
Over the last four reported quarters, Novartis generated $56.05B in revenue and $13.53B in net income.
Novartis's next earnings report is scheduled for July 21, 2026 before market open; analysts estimate EPS of $2.17.
Novartis quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q1 2026 | $13.52B | -0.7% | $3.16B | $1.65 |
| Q4 2025 | $13.33B | -1.6% | $2.41B | $1.25 |
| Q3 2025 | $14.36B | +9.0% | $3.93B | $2.02 |
| Q2 2025 | $14.84B | +15.3% | $4.04B | $2.06 |
| Q1 2025 | $13.62B | +12.4% | $3.61B | $1.82 |
| Q4 2024 | $13.56B | +15.1% | $2.82B | $1.41 |
| Q3 2024 | $13.17B | +8.9% | $3.19B | $1.57 |
| Q2 2024 | $12.87B | +9.6% | $3.25B | $1.59 |
Novartis (NVS) — frequently asked questions
When does Novartis (NVS) report earnings next?
Novartis is expected to report earnings on July 21, 2026 before market open. Analysts estimate EPS of $2.17.
What was NVS's revenue last quarter?
Novartis reported revenue of $13.52B in Q1 2026, down 0.7% from the same quarter a year earlier.
What was NVS's EPS last quarter?
Novartis reported diluted EPS of $1.65 in Q1 2026.
Is Novartis profitable?
Novartis is currently profitable, with $13.53B in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Merck (MRK)